Is OVID or PBM more undervalued in 2026?

CirclFi compares Ovid Therapeutics Inc. (OVID) and Psyence Biomedical Ltd. (PBM) using 13 institutional-grade valuation models. OVID has a Quality of Company score of 5.3/10 while PBM scores 1.7/10.

Which is a better buy — OVID or PBM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OVID and PBM valuations compare?

OVID at $2.64 and PBM at $4.37 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OVID vs PBM Valuation Comparison 2026 — Intrinsic Value Analysis

OVID

Biotechnology

Ovid Therapeutics Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.64

Last close

Models

9/13

Active

PBM

Biotechnology

Psyence Biomedical Ltd.

Quality

1.7

out of 10

Value Trap

—

Price

$4.37

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	OVID Fair Value	OVID Upside	PBM Fair Value	PBM Upside
Bayesian DCF	Intrinsic	$0.80	-69.8%	$1.16	-73.5%
Earnings Power Value	Intrinsic	—	—	$10.33	+65.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.83	-68.7%	$19.81	+358.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OVID vs PBM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OVID vs PBM — Which Stock Is More Undervalued?

OVID scores higher with a 5.3/10 quality rating vs PBM's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ovid Therapeutics Inc. (OVID) and Psyence Biomedical Ltd. (PBM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OVID currently trades at $2.64 with a QOC of 5.3/10, while PBM trades at $4.37 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).